HRP20150282T4 - Purifikacija protutijela pomoću kromatografije kationskom izmjenom - Google Patents
Purifikacija protutijela pomoću kromatografije kationskom izmjenom Download PDFInfo
- Publication number
- HRP20150282T4 HRP20150282T4 HRP20150282TT HRP20150282T HRP20150282T4 HR P20150282 T4 HRP20150282 T4 HR P20150282T4 HR P20150282T T HRP20150282T T HR P20150282TT HR P20150282 T HRP20150282 T HR P20150282T HR P20150282 T4 HRP20150282 T4 HR P20150282T4
- Authority
- HR
- Croatia
- Prior art keywords
- cation exchange
- antibody
- value
- washing
- buffer
- Prior art date
Links
- 238000011091 antibody purification Methods 0.000 title 1
- 238000005277 cation exchange chromatography Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims 11
- 238000005341 cation exchange Methods 0.000 claims 9
- 239000000463 material Substances 0.000 claims 9
- 239000012149 elution buffer Substances 0.000 claims 8
- 239000011534 wash buffer Substances 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 238000005406 washing Methods 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- -1 poly(styrene-divinylbenzene) Polymers 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 241000699802 Cricetulus griseus Species 0.000 claims 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 229960000397 bevacizumab Drugs 0.000 claims 2
- 239000006143 cell culture medium Substances 0.000 claims 2
- 239000000356 contaminant Substances 0.000 claims 2
- 238000010828 elution Methods 0.000 claims 2
- 229940072360 garamycin Drugs 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims 1
- 238000011109 contamination Methods 0.000 claims 1
- 102000058223 human VEGFA Human genes 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Claims (9)
1. Postupak purifikacije protutijela iz sastava koji sadrži protutijelo i najmanje jedno sredstvo kontaminacije, naznačen time, da taj postupak obuhvaća niz uzastopnih koraka kako slijedi:
(a) punjenje sastava na materijalu kationske izmjene gdje sastav prvo ima pH-vrijednost od 4,0 do 6,0;
(b) ispiranje materijala kationske izmjene s prvim puferom za ispiranje, gdje je
pH-vrijednost prvog pufera za ispiranje od 6,8 do 9,0;
(c) ispiranje materijala kationske izmjene s drugim puferom za ispiranje na
pH-vrijednosti od 5,0 do 6,0; i
(d) eluacija protutijela iz materijala kationske izmjene s puferom za eluiranje pod provodljivošću koja je najmanje 2mS/cm veća nego ona od drugog pufera za ispiranje;
pri čemu protutijelo je bevacizumab.
2. Postupak prema zahtjevu 1, naznačen time, da je pH-vrijednost od drugog pufera za ispiranje otprilike ista kao i pH-vrijednost od pufera za eluiranje.
3. Postupak prema zahtjevu 1, naznačen time, da pH-vrijednost od sastava u koraku (a) iznosi od 4,0 do 6,0, pH-vrijednost prvog pufera za ispiranje iznosi od 6,8 do 8,0,
pH-vrijednost drugog pufera za ispiranje iznosi od 5,0 do 6,0, i pH-vrijednost pufera za eluiranje iznosi od 5,0 do 6,0.
4. Postupak prema zahtjevu 1, naznačen time, da je provodljivost pufera za eluiranje od
10 mS/cm do 100 mS/cm.
5. Postupak prema zahtjevu 1, naznačen time, da pufer za eluiranje sadrži NaCl u količini od 100 do 300 mM.
6. Postupak prema zahtjevu 1, naznačen time, da materijal kationske izmjene obuhvaća šuplje protočne čestice križno povezanog poli(stiren-divinilbenzena), koje su obložene s polihidroksiliranim polimerom funkcionaliziranim sa sulfopropilnim skupinama.
7. Postupak prema zahtjevu 1, naznačen time, da je sredstvo kontaminacije odabrano iz skupine koju čine proteini jajnika kineskog hrčka (CHOP), lužinom isprani protein A, DNK, agregirano protutijelo, sastojak medija za kultiviranje stanice, garamicin i virusni kontaminant.
8. Postupak purifikacije protutijela koje se veže na ljudski vaskularni endotelijalni faktor rasta (VEGF) iz sastava koji sadrži protutijelo i jedno ili više sredstava kontaminacije odabranih iz skupine koju čine sastojak medija za kultiviranje stanice, garamicin, proteini jajnika kineskog hrčka (CHOP), DNK, virusni kontaminant i agregirano protutijelo VEGF, naznačen time, da taj postupak obuhvaća niz uzastopnih koraka kako slijedi:
(a) punjenje sastava na materijalu kationske izmjene gdje sastav ima pH-vrijednost od 4,0 do 6,0;
(b) ispiranje materijala kationske izmjene s prvim puferom za ispiranje na
pH-vrijednosti od 6,8 do 8,0;
(c) ispiranje materijala kationske izmjene s drugim puferom za ispiranje na
pH-vrijednosti od 5,0 do 6,0; i
(d) eluacija protutijela iz materijala kationske izmjene uporabom pufera za eluiranje na pH-vrijednosti od 5,0 do 6,0 i pod provodljivošću od 10 mS/cm do 100 mS/cm,
pri čemu protutijelo je bevacizumab.
9. Postupak prema zahtjevu 13, naznačen time, da pufer za eluiranje sadrži NaCl u količini od 100 do 300 mM.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98382507P | 2007-10-30 | 2007-10-30 | |
EP08844379.1A EP2215117B2 (en) | 2007-10-30 | 2008-10-29 | Antibody purification by cation exchange chromatography |
PCT/US2008/081516 WO2009058812A1 (en) | 2007-10-30 | 2008-10-29 | Antibody purification by cation exchange chromatography |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20150282T1 HRP20150282T1 (hr) | 2015-06-19 |
HRP20150282T4 true HRP20150282T4 (hr) | 2018-08-10 |
Family
ID=40262967
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20150282TT HRP20150282T4 (hr) | 2007-10-30 | 2015-03-12 | Purifikacija protutijela pomoću kromatografije kationskom izmjenom |
HRP20180943TT HRP20180943T1 (hr) | 2007-10-30 | 2018-06-18 | Pročišćavanje protutijela preko kromatografije kationske izmjene |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20180943TT HRP20180943T1 (hr) | 2007-10-30 | 2018-06-18 | Pročišćavanje protutijela preko kromatografije kationske izmjene |
Country Status (32)
Country | Link |
---|---|
US (3) | US20090148435A1 (hr) |
EP (4) | EP2840090B1 (hr) |
JP (5) | JP5237382B2 (hr) |
KR (3) | KR20150008503A (hr) |
CN (3) | CN101889025B (hr) |
AR (2) | AR069097A1 (hr) |
AU (1) | AU2008318865B2 (hr) |
BR (1) | BRPI0817182A2 (hr) |
CA (1) | CA2703279C (hr) |
CL (1) | CL2008003218A1 (hr) |
CO (1) | CO6280422A2 (hr) |
CY (1) | CY1116129T1 (hr) |
DK (3) | DK2215117T4 (hr) |
ES (3) | ES2666170T3 (hr) |
HK (4) | HK1143821A1 (hr) |
HR (2) | HRP20150282T4 (hr) |
HU (3) | HUE024877T2 (hr) |
IL (4) | IL205310A0 (hr) |
ME (1) | ME02101B (hr) |
MX (1) | MX2010004740A (hr) |
NZ (1) | NZ584839A (hr) |
PE (1) | PE20091434A1 (hr) |
PH (1) | PH12013501128A1 (hr) |
PL (3) | PL2840090T3 (hr) |
PT (1) | PT2215117E (hr) |
RS (1) | RS53850B2 (hr) |
RU (1) | RU2498991C2 (hr) |
SG (2) | SG175597A1 (hr) |
SI (3) | SI2215117T2 (hr) |
TW (2) | TWI448330B (hr) |
WO (1) | WO2009058812A1 (hr) |
ZA (2) | ZA201002850B (hr) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2380911T (lt) * | 2003-11-05 | 2018-07-10 | Roche Glycart Ag | Antigeną surišančios molekulės, pasižyminčios padidintu fc receptoriaus surišimo afiniškumu ir efektoriaus funkcija |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
CN101141981A (zh) * | 2005-01-21 | 2008-03-12 | 健泰科生物技术公司 | Her抗体的固定剂量给药 |
EP2399605A1 (en) | 2005-02-23 | 2011-12-28 | Genentech, Inc. | Extending time to disease progression or survival in cancer patients |
KR20090074040A (ko) | 2006-09-13 | 2009-07-03 | 아보트 러보러터리즈 | 세포 배양의 개선 |
US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
WO2008109440A2 (en) | 2007-03-02 | 2008-09-12 | Genentech, Inc. | Predicting response to a her dimerisation inhibitor based on low her3 expression |
ES2666170T3 (es) * | 2007-10-30 | 2018-05-03 | Genentech, Inc. | Purificación de anticuerpos mediante cromatografía de intercambio catiónico |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
SG10201702951RA (en) | 2008-10-20 | 2017-06-29 | Abbvie Inc | Viral inactivation during purification of antibodies |
SG10201702922VA (en) | 2008-10-20 | 2017-06-29 | Abbvie Inc | Isolation and purification of antibodies using protein a affinity chromatography |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
US20120178910A1 (en) * | 2009-09-23 | 2012-07-12 | Medarex, Inc. | Cation exchange chromatography (methods) |
CN103237810A (zh) * | 2010-02-23 | 2013-08-07 | 霍夫曼-拉罗奇有限公司 | 用于治疗卵巢癌的抗血管发生疗法 |
AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
PL2552961T3 (pl) * | 2010-03-30 | 2018-04-30 | Janssen Biotech, Inc. | Humanizowane przeciwciała il-25 |
PL3333265T3 (pl) | 2010-05-14 | 2020-08-10 | Oregon Health & Science University | Rekombinowane wektory HCMV i RHCMV kodujące heterologiczny antygen wyizolowany z wirusa zapalenia wątroby typu B oraz ich zastosowania |
CN102905718A (zh) * | 2010-05-25 | 2013-01-30 | 弗·哈夫曼-拉罗切有限公司 | 纯化多肽的方法 |
GB201012603D0 (en) | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Protein purification |
EP2655412B1 (en) * | 2010-12-21 | 2018-01-17 | F. Hoffmann-La Roche AG | Isoform enriched antibody preparation and method for obtaining it |
CA2831787A1 (en) | 2011-03-29 | 2012-10-04 | Glaxosmithkline Llc | Buffer system for protein purification |
EP2714713B1 (en) * | 2011-05-26 | 2018-05-09 | Dr. Reddy's Laboratories Limited | Purification of anti-cd20 antibodies |
CA2832109C (en) | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
WO2013054250A1 (en) * | 2011-10-10 | 2013-04-18 | Dr Reddy's Laboratories Limited | Purification method |
CN104334189A (zh) | 2011-10-14 | 2015-02-04 | 霍夫曼-拉罗奇有限公司 | Her2二聚化抑制剂帕妥珠单抗的用途和包含her2二聚化抑制剂帕妥珠单抗的制品 |
RU2478646C1 (ru) * | 2011-11-28 | 2013-04-10 | Федеральное государственное бюджетное учреждение науки Институт молекулярной биологии им.В.А.Энгельгардта Российской академии наук (ИМБ РАН) | Способ получения высокоаффинных поликлональных антител |
EP2794635B8 (en) | 2011-12-22 | 2018-11-14 | H. Hoffnabb-La Roche Ag | Ion exchange membrane chromatography |
WO2014009465A1 (en) | 2012-07-13 | 2014-01-16 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
EP2889617B1 (en) * | 2012-08-27 | 2017-10-11 | Asahi Kasei Medical Co., Ltd. | Antibody purification method by means of temperature-responsive chromatography |
CN103217499B (zh) * | 2013-01-15 | 2015-12-02 | 珠海市丽珠单抗生物技术有限公司 | 一种测定免疫球蛋白电荷异构体的糖基化和末端修饰情况的方法 |
SG10201709131UA (en) | 2013-03-08 | 2017-12-28 | Genzyme Corp | Continuous purification of therapeutic proteins |
UY35517A (es) * | 2013-04-04 | 2014-10-31 | Mabxience S A | Un procedimiento para aumentar la formación de ácido piroglutamico de una proteína |
NZ751877A (en) | 2013-04-16 | 2020-04-24 | Genentech Inc | Pertuzumab variants and evaluation thereof |
US10351592B2 (en) | 2013-10-30 | 2019-07-16 | Celltrion, Inc. | Method for separating antibody isoforms using cation exchange chromatography |
CN104628846B (zh) * | 2013-11-06 | 2019-12-06 | 三生国健药业(上海)股份有限公司 | 重组蛋白质的纯化方法 |
ES2753269T3 (es) | 2013-11-25 | 2020-04-07 | Seattle Genetics Inc | Preparación de anticuerpos a partir del cultivo de células CHO para conjugación |
TWI709570B (zh) | 2014-01-17 | 2020-11-11 | 美商健臻公司 | 無菌層析法及製法 |
TWI709569B (zh) | 2014-01-17 | 2020-11-11 | 美商健臻公司 | 無菌層析樹脂及其用於製造方法的用途 |
KR20230136616A (ko) * | 2014-02-04 | 2023-09-26 | 바이오젠 엠에이 인코포레이티드 | 번역 후 변형을 강화시키기 위한 통류 방식 양이온교환 크로마토그래피의 용도 |
KR101921552B1 (ko) | 2014-03-10 | 2018-11-23 | 리히터 게데온 닐트. | 사전 세정 단계를 이용하는 면역글로불린 정제 |
CN105017418B (zh) * | 2014-03-27 | 2021-02-23 | 上海药明康德新药开发有限公司 | 单克隆抗体纯化工艺方法 |
CA2946860A1 (en) | 2014-04-25 | 2015-10-29 | Genentech, Inc. | Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab |
CA2955306C (en) | 2014-07-16 | 2021-06-01 | Oregon Health & Science University | Human cytomegalovirus comprising exogenous antigens |
CN105315369B (zh) * | 2014-07-25 | 2020-03-13 | 山东博安生物技术有限公司 | 利用阳离子交换层析纯化蛋白质 |
WO2016149088A1 (en) * | 2015-03-13 | 2016-09-22 | Bristol-Myers Squibb Company | Use of alkaline washes during chromatography to remove impurities |
EP3302551B1 (en) | 2015-05-30 | 2024-06-26 | F. Hoffmann-La Roche AG | Methods of treating her2-positive previously untreated metastatic breast cancer |
KR101657690B1 (ko) * | 2015-06-05 | 2016-09-19 | 주식회사 녹십자홀딩스 | 혈장 유래 b형 간염 사람 면역글로불린 제제의 제조방법 |
WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
CN108474003A (zh) | 2015-11-20 | 2018-08-31 | 俄勒冈健康与科学大学 | 包含微小rna识别元件的cmv载体 |
GB201600512D0 (en) | 2016-01-12 | 2016-02-24 | Univ York | Recombinant protein production |
JP7046828B2 (ja) | 2016-04-15 | 2022-04-04 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 滲出型加齢性黄斑変性の治療のための組成物 |
CN109310756B (zh) * | 2016-05-13 | 2022-06-28 | 奥美药业有限公司 | 新型血管生成素2,vegf双特异性拮抗剂 |
EP3484911B1 (en) * | 2016-07-15 | 2020-11-04 | H. Hoffnabb-La Roche Ag | Method for purifying pegylated erythropoietin |
CN106222222B (zh) * | 2016-08-08 | 2019-10-29 | 湖北医药学院 | 一种重组人白血病抑制因子的制备方法 |
WO2018045587A1 (zh) * | 2016-09-12 | 2018-03-15 | 广东东阳光药业有限公司 | 一种抗vegf类单克隆抗体的纯化方法 |
CN106380519B (zh) * | 2016-10-17 | 2019-11-01 | 深圳万乐药业有限公司 | 一种单克隆抗体的纯化方法 |
EP3529363A4 (en) | 2016-10-18 | 2020-05-06 | Oregon Health & Science University | CYTOMEGALOVIRUS VECTORS, CALLING OUT T-CELLS, RESTRICTED BY A LARGE HISTOCOMPATIBILITY COMPLEX E-MOLECULE |
WO2018078158A1 (en) * | 2016-10-31 | 2018-05-03 | Hexal Ag | Antibody preparation |
US20180221481A1 (en) | 2016-12-28 | 2018-08-09 | Genentech, Inc. | Treatment of advanced her2 expressing cancer |
CA3047349C (en) | 2017-01-17 | 2020-09-22 | Genentech, Inc. | Subcutaneous her2 antibody formulations |
RS65204B1 (sr) | 2017-03-02 | 2024-03-29 | Genentech Inc | Adjuvansni tretman her2-pozitivnog raka dojke |
BE1025090B1 (fr) | 2017-03-30 | 2018-10-29 | Univercells Sa | Procede et kit de purification de proteines |
TWI679209B (zh) * | 2017-04-14 | 2019-12-11 | 南韓商Cj醫藥健康股份有限公司 | 使用陽離子交換層析法純化同功抗體之方法 |
WO2018200505A1 (en) | 2017-04-24 | 2018-11-01 | Genentech, Inc. | Erbb2/her2 mutations in the transmbrane or juxtamembrane domain |
JP2020525445A (ja) | 2017-06-21 | 2020-08-27 | セファロン・インコーポレイテッドCephalon,Incorporated | カチオン交換クロマトグラフィーの洗浄緩衝液 |
CN111163804A (zh) * | 2017-09-22 | 2020-05-15 | 伊缪诺金公司 | 使用阳离子交换色谱法分离三轻链抗体 |
CN110272491B (zh) * | 2018-03-13 | 2023-01-24 | 江苏恒瑞医药股份有限公司 | 一种抗pd-1抗体的纯化工艺 |
KR20200136464A (ko) * | 2018-03-29 | 2020-12-07 | 브리스톨-마이어스 스큅 컴퍼니 | 단량체성 모노클로날 항체를 정제하는 방법 |
EP3791172B1 (en) * | 2018-05-08 | 2023-06-28 | Waters Technologies Corporation | Methods, compositions and kits useful for ph gradient cation exchange chromatography |
BR112021003420A2 (pt) | 2018-08-31 | 2021-05-18 | Genzyme Corporation | resina cromatográfica estéril e uso da mesma em processos de manufatura |
EP3643322A1 (en) * | 2018-10-26 | 2020-04-29 | Mabion SA | Low aggregate anti cd20 ligand formulation |
CN109320611B (zh) * | 2018-10-31 | 2022-06-03 | 鼎康(武汉)生物医药有限公司 | 一种人鼠嵌合单克隆抗体生物类似药的纯化方法 |
CN112206327A (zh) * | 2019-07-12 | 2021-01-12 | 上海药明生物技术有限公司 | 一种抗体偶联药物的制备及其高通量筛选方法 |
EP4045917A1 (en) * | 2019-10-14 | 2022-08-24 | Pierce Biotechnology, Inc. | Peptide purification formulations and methods |
CA3162748A1 (en) * | 2019-11-25 | 2021-06-03 | Akeso Biopharma, Inc. | Anti-pd-1-anti-vegfa bispecific antibody, pharmaceutical composition and use thereof |
KR102153258B1 (ko) * | 2020-02-21 | 2020-09-07 | 프레스티지바이오로직스 주식회사 | 베바시주맙 정제의 최적화된 방법 |
US11416468B2 (en) * | 2020-07-21 | 2022-08-16 | International Business Machines Corporation | Active-active system index management |
CN114591438B (zh) * | 2022-04-25 | 2023-12-05 | 达石药业(广东)有限公司 | 一种采用阳离子交换层析法纯化双特异性抗体的方法 |
WO2024090489A1 (ja) * | 2022-10-26 | 2024-05-02 | 日本メジフィジックス株式会社 | 放射性医薬組成物の製造方法 |
CN115850493B (zh) * | 2022-11-08 | 2024-03-12 | 江苏耀海生物制药有限公司 | 一种二价纳米抗体Cablivi的分离纯化方法 |
Family Cites Families (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4515893A (en) | 1979-04-26 | 1985-05-07 | Ortho Pharmaceutical Corporation | Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells |
GB2070818A (en) | 1980-02-04 | 1981-09-09 | Philips Electronic Associated | Regulated power supply for an image intensifier |
WO1984002129A1 (en) | 1982-11-22 | 1984-06-07 | Takeda Chemical Industries Ltd | Human immune interferon protein and process for its preparation |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
US5169774A (en) | 1984-02-08 | 1992-12-08 | Cetus Oncology Corporation | Monoclonal anti-human breast cancer antibodies |
US4753894A (en) * | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
WO1986002068A1 (en) * | 1984-09-26 | 1986-04-10 | Takeda Chemical Industries, Ltd. | Mutual separation of proteins |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US5196323A (en) | 1985-04-27 | 1993-03-23 | Boehringer Ingelheim International Gmbh | Process for preparing and purifying alpha-interferon |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US5525338A (en) | 1992-08-21 | 1996-06-11 | Immunomedics, Inc. | Detection and therapy of lesions with biotin/avidin conjugates |
US5091178A (en) | 1986-02-21 | 1992-02-25 | Oncogen | Tumor therapy with biologically active anti-tumor antibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
CA1283072C (en) | 1986-12-01 | 1991-04-16 | Timothy Durance | Process for the isolation and separation of lysozyme and avidin from eggwhite |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5451662A (en) | 1987-10-23 | 1995-09-19 | Schering Corporation | Method of purifying protein |
US5118796A (en) * | 1987-12-09 | 1992-06-02 | Centocor, Incorporated | Efficient large-scale purification of immunoglobulins and derivatives |
US5091313A (en) | 1988-08-05 | 1992-02-25 | Tanox Biosystems, Inc. | Antigenic epitopes of IgE present on B cell but not basophil surface |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
IT1219874B (it) | 1988-03-18 | 1990-05-24 | Fidia Farmaceutici | Utilizzazione del fattore di crescita nervoso umano e sue composizioni farmaceutiche |
US5115101A (en) | 1988-06-08 | 1992-05-19 | Miles Inc. | Removal of protein A from antibody preparations |
WO1989012463A1 (en) | 1988-06-21 | 1989-12-28 | Genentech, Inc. | Method and therapeutic compositions for the treatment of myocardial infarction |
DE68925971T2 (de) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5112951A (en) | 1989-07-28 | 1992-05-12 | Hybritech Incorporated | Separation of anti-metal chelate antibodies |
US5110913A (en) | 1990-05-25 | 1992-05-05 | Miles Inc. | Antibody purification method |
EP0467466A1 (en) * | 1990-07-16 | 1992-01-22 | Eastman Kodak Company | Method for the purification of immunoreactive labeled thyroxine conjugates |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
ATE233813T1 (de) | 1991-08-14 | 2003-03-15 | Genentech Inc | Veränderte immunglobuline für spezifische fc- epsilon rezeptoren |
EP0861893A3 (en) | 1991-09-19 | 1999-11-10 | Genentech, Inc. | High level expression of immunoglobulin polypeptides |
EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
JPH05202098A (ja) | 1992-01-29 | 1993-08-10 | Snow Brand Milk Prod Co Ltd | 乳質原料から生理活性物質の製造法 |
DE69334255D1 (de) | 1992-02-06 | 2009-02-12 | Novartis Vaccines & Diagnostic | Marker für Krebs und biosynthetisches Bindeprotein dafür |
US5279823A (en) * | 1992-06-08 | 1994-01-18 | Genentech, Inc. | Purified forms of DNASE |
CA2140933A1 (en) | 1992-08-21 | 1994-02-22 | Paula M. Jardieu | Method for treating an lfa-1 mediated disorder |
DE69329503T2 (de) | 1992-11-13 | 2001-05-03 | Idec Pharma Corp | Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
ES2108566T3 (es) | 1993-12-10 | 1997-12-16 | Genentech Inc | Procedimientos para diagnosticar alergias y para seleccionar agentes terapeuticos antialergicos. |
EP0739214B1 (en) | 1994-01-18 | 1998-03-18 | Genentech, Inc. | A METHOD OF TREATMENT OF PARASITIC INFECTION USING IgE ANTAGONISTS |
US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
CA2181787A1 (en) | 1994-03-03 | 1995-09-08 | Claire M. Doerschuk | Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders |
US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5714583A (en) | 1995-06-07 | 1998-02-03 | Genetics Institute, Inc. | Factor IX purification methods |
CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
ATE222774T1 (de) | 1996-01-23 | 2002-09-15 | Genentech Inc | Antikörper gegen cd 18 zur verwendung gegen gehirnschlag |
US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
NZ335207A (en) * | 1996-11-15 | 2000-09-29 | Genentech Inc | Process to isolate recombinant human neurotrophin using hydrophobic chromatography resin |
ES2337091T3 (es) | 1996-11-27 | 2010-04-20 | Genentech, Inc. | Purificacion por afinidad de polipeptido en una matriz de proteina. |
AU731817C (en) | 1996-11-27 | 2001-11-01 | Genentech Inc. | Humanized anti-CD11a antibodies |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
SI1325932T1 (hr) | 1997-04-07 | 2005-08-31 | Genentech Inc | |
DE69841815D1 (de) | 1997-04-07 | 2010-09-16 | Genentech Inc | Anti-VEGF Antikörper |
EP1860187B1 (en) | 1997-05-15 | 2011-07-13 | Genentech, Inc. | Apo-2 receptor |
US5994511A (en) | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
PT1308455E (pt) | 1998-05-06 | 2006-08-31 | Genentech Inc | Composicao compreendendo anticorpos anti-her2 |
ATE274522T1 (de) | 1998-06-01 | 2004-09-15 | Genentech Inc | Abtrennung von antikörper-monomeren von deren multimeren mittels ionaustausch-chromatographie |
IL140155A (en) | 1998-06-09 | 2005-12-18 | Statens Seruminstitut | Process for producing immunoglobulins for intravenous administration and other immunoglobulin products |
EP2112167A3 (en) | 1999-06-25 | 2010-12-22 | Genentech, Inc. | Humanized ANTI-ERBB2 antibodies and treatment with ANTI-ERBB2 antibodies |
ES2309012T3 (es) | 1999-10-29 | 2008-12-16 | Genentech, Inc. | Composiciones del anticuerpo anti-psca y a sus procedimientos contra celulas cancerigenas que expresen psca. |
UA83458C2 (uk) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
US6417355B1 (en) * | 2001-04-11 | 2002-07-09 | The United States Of America As Represented By The Secretary Of The Navy | Geminal-dinitro-1-5 diazocine derivatives |
GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
US6770027B2 (en) * | 2001-10-05 | 2004-08-03 | Scimed Life Systems, Inc. | Robotic endoscope with wireless interface |
WO2003033658A2 (en) | 2001-10-17 | 2003-04-24 | Human Genome Sciences, Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
CN101914158A (zh) | 2002-02-14 | 2010-12-15 | 免疫医疗公司 | 抗cd 20抗体及其融合蛋白和使用方法 |
CA2490423A1 (en) * | 2002-06-21 | 2003-12-31 | Biogen Idec Inc. | Buffered formulations for concentrating antibodies and methods of use thereof |
AU2003265994B2 (en) * | 2002-09-11 | 2010-04-01 | Genentech, Inc. | Protein purification |
KR20090088973A (ko) | 2002-10-17 | 2009-08-20 | 젠맵 에이/에스 | Cd20에 대한 인간 모노클로날 항체 |
MXPA05006306A (es) | 2002-12-13 | 2005-09-21 | Mitra Medical Technology Ab | Agentes de direccionamiento antilinfoma con funciones efectoras y de afinidad enlazados a traves de un reactivo trifuncional. |
SI2289936T1 (sl) | 2002-12-16 | 2017-10-30 | Genentech, Inc. | Imunoglobulinske variante in njihove uporabe |
JP2006523609A (ja) | 2002-12-31 | 2006-10-19 | アルタス ファーマシューティカルズ インコーポレイテッド | タンパク質結晶およびイオン性ポリマーの複合体 |
EP1614693A4 (en) * | 2003-03-31 | 2006-07-19 | Kirin Brewery | PURIFICATION OF A HUMAN MONOCLONAL ANTIBODY AND A HUMAN POLYCLONAL ANTIBODY |
CA2897608C (en) | 2003-05-09 | 2018-07-31 | Duke University | Cd20-specific antibodies and methods employing same |
AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
WO2005014618A2 (en) | 2003-08-08 | 2005-02-17 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
US8147832B2 (en) | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
KR100524074B1 (ko) | 2003-10-01 | 2005-10-26 | 삼성전자주식회사 | 베젤 구조를 가지는 전자기기 |
TW200533357A (en) * | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
RU2006140374A (ru) † | 2004-04-16 | 2008-05-27 | Дженентек, Инк. (Us) | Лечение нарушений |
CN101022829A (zh) * | 2004-04-16 | 2007-08-22 | 健泰科生物技术公司 | 用抗cd20抗体治疗多软骨炎和多发性单神经炎 |
EP1833970A2 (en) * | 2004-12-22 | 2007-09-19 | Genentech, Inc. | Methods for producing soluble multi-membrane-spanning proteins |
HUE049797T2 (hu) * | 2005-03-11 | 2020-10-28 | Wyeth Llc | Gyenge megoszlási kromatográfiás eljárás |
CN101365722A (zh) * | 2005-06-17 | 2009-02-11 | 艾兰制药国际有限公司 | 纯化抗Aβ抗体的方法 |
WO2007028154A2 (en) * | 2005-09-02 | 2007-03-08 | Northwestern University | Encapsulated arsenic drugs |
CN101437839A (zh) * | 2006-03-20 | 2009-05-20 | 米德列斯公司 | 蛋白质纯化 |
NZ611859A (en) * | 2006-04-05 | 2014-12-24 | Abbvie Biotechnology Ltd | Antibody purification |
KR101770312B1 (ko) * | 2006-08-28 | 2017-08-22 | 아레스 트레이딩 에스.에이. | Fc함유 단백질을 정제하는 방법 |
US8620738B2 (en) | 2006-08-31 | 2013-12-31 | Visa U.S.A. Inc | Loyalty program incentive determination |
US20110130544A1 (en) * | 2007-03-30 | 2011-06-02 | Medimmune, Llc | Antibodies with decreased deamidation profiles |
ES2666170T3 (es) * | 2007-10-30 | 2018-05-03 | Genentech, Inc. | Purificación de anticuerpos mediante cromatografía de intercambio catiónico |
US9813410B2 (en) | 2014-06-26 | 2017-11-07 | Rakuten, Inc. | Information processing apparatus, information processing method, and information processing program |
-
2008
- 2008-10-29 ES ES14189095.4T patent/ES2666170T3/es active Active
- 2008-10-29 HU HUE08844379A patent/HUE024877T2/en unknown
- 2008-10-29 MX MX2010004740A patent/MX2010004740A/es active IP Right Grant
- 2008-10-29 PE PE2008001848A patent/PE20091434A1/es active IP Right Grant
- 2008-10-29 KR KR1020147036127A patent/KR20150008503A/ko not_active Application Discontinuation
- 2008-10-29 AR ARP080104725A patent/AR069097A1/es active IP Right Grant
- 2008-10-29 HU HUE14189095A patent/HUE037409T2/hu unknown
- 2008-10-29 SG SG2011073087A patent/SG175597A1/en unknown
- 2008-10-29 EP EP14189095.4A patent/EP2840090B1/en active Active
- 2008-10-29 KR KR1020127028627A patent/KR20140015166A/ko not_active Application Discontinuation
- 2008-10-29 AU AU2008318865A patent/AU2008318865B2/en active Active
- 2008-10-29 SI SI200831381T patent/SI2215117T2/en unknown
- 2008-10-29 SI SI200831945T patent/SI2840090T1/en unknown
- 2008-10-29 HU HUE12189190A patent/HUE027668T2/en unknown
- 2008-10-29 DK DK08844379.1T patent/DK2215117T4/en active
- 2008-10-29 CA CA2703279A patent/CA2703279C/en active Active
- 2008-10-29 SI SI200831634A patent/SI2565206T1/sl unknown
- 2008-10-29 EP EP12189190.7A patent/EP2565206B1/en active Active
- 2008-10-29 PL PL14189095T patent/PL2840090T3/pl unknown
- 2008-10-29 EP EP08844379.1A patent/EP2215117B2/en active Active
- 2008-10-29 DK DK12189190.7T patent/DK2565206T3/en active
- 2008-10-29 DK DK14189095.4T patent/DK2840090T3/en active
- 2008-10-29 RS RS20150156A patent/RS53850B2/sr unknown
- 2008-10-29 CN CN200880119331XA patent/CN101889025B/zh active Active
- 2008-10-29 US US12/260,623 patent/US20090148435A1/en not_active Abandoned
- 2008-10-29 PT PT88443791T patent/PT2215117E/pt unknown
- 2008-10-29 PL PL08844379T patent/PL2215117T5/pl unknown
- 2008-10-29 SG SG10201401690XA patent/SG10201401690XA/en unknown
- 2008-10-29 CN CN201310495290.7A patent/CN103554215B/zh active Active
- 2008-10-29 RU RU2010121816/10A patent/RU2498991C2/ru active
- 2008-10-29 PL PL12189190T patent/PL2565206T3/pl unknown
- 2008-10-29 KR KR1020107011765A patent/KR101241486B1/ko active IP Right Grant
- 2008-10-29 WO PCT/US2008/081516 patent/WO2009058812A1/en active Application Filing
- 2008-10-29 TW TW097141614A patent/TWI448330B/zh active
- 2008-10-29 ME MEP-2015-34A patent/ME02101B/me unknown
- 2008-10-29 ES ES12189190.7T patent/ES2572958T3/es active Active
- 2008-10-29 CL CL2008003218A patent/CL2008003218A1/es unknown
- 2008-10-29 ES ES08844379.1T patent/ES2533266T5/es active Active
- 2008-10-29 CN CN201510941252.9A patent/CN105315323A/zh active Pending
- 2008-10-29 TW TW103117553A patent/TWI554517B/zh active
- 2008-10-29 BR BRPI0817182 patent/BRPI0817182A2/pt not_active Application Discontinuation
- 2008-10-29 NZ NZ584839A patent/NZ584839A/en unknown
- 2008-10-29 JP JP2010532193A patent/JP5237382B2/ja active Active
- 2008-10-29 EP EP18151178.3A patent/EP3441402A1/en not_active Withdrawn
-
2010
- 2010-04-22 ZA ZA2010/02850A patent/ZA201002850B/en unknown
- 2010-04-25 IL IL205310A patent/IL205310A0/en unknown
- 2010-05-21 CO CO10061141A patent/CO6280422A2/es active IP Right Grant
- 2010-10-28 HK HK10110121.9A patent/HK1143821A1/xx active IP Right Maintenance
- 2010-10-28 HK HK13109765.9A patent/HK1182401A1/zh unknown
-
2011
- 2011-03-23 ZA ZA2011/02169A patent/ZA201102169B/en unknown
-
2013
- 2013-03-21 JP JP2013059102A patent/JP2013173747A/ja not_active Withdrawn
- 2013-06-03 PH PH12013501128A patent/PH12013501128A1/en unknown
-
2014
- 2014-09-30 IL IL234902A patent/IL234902A0/en unknown
- 2014-09-30 IL IL234901A patent/IL234901A0/en unknown
- 2014-11-03 US US14/531,880 patent/US9896478B2/en active Active
-
2015
- 2015-02-19 JP JP2015030881A patent/JP2015155406A/ja not_active Withdrawn
- 2015-02-19 JP JP2015030880A patent/JP5885864B2/ja active Active
- 2015-03-12 HR HRP20150282TT patent/HRP20150282T4/hr unknown
- 2015-03-19 CY CY20151100275T patent/CY1116129T1/el unknown
- 2015-06-18 IL IL239495A patent/IL239495B/en not_active IP Right Cessation
- 2015-07-28 HK HK15107237.1A patent/HK1206753A1/xx unknown
-
2016
- 2016-07-12 JP JP2016137986A patent/JP2017019790A/ja active Pending
- 2016-08-08 HK HK16109407.0A patent/HK1221234A1/zh unknown
-
2017
- 2017-12-21 US US15/850,885 patent/US20180118781A1/en not_active Abandoned
-
2018
- 2018-03-09 AR ARP180100555A patent/AR111171A2/es unknown
- 2018-06-18 HR HRP20180943TT patent/HRP20180943T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20150282T4 (hr) | Purifikacija protutijela pomoću kromatografije kationskom izmjenom | |
HRP20171095T4 (hr) | Postupci pročišćavanja polipeptida | |
HRP20201118T1 (hr) | Izolacija i pročišćavanje prot-il-13 protutijela uporabom protein a afinitetne kromatografije | |
US10053489B2 (en) | Method for purifying antibody | |
JP2013530156A5 (hr) | ||
JP7049487B2 (ja) | 細胞培養用温度応答性基材 | |
JP2014532718A5 (hr) | ||
US11014129B2 (en) | Methods of cleaning a protein A based affinity chromatography column | |
CA2784959C (en) | Chromatographic method for purifying fc-containing proteins | |
CN104487446B (zh) | 利用混合的多官能性表面降低蛋白制剂中聚集物含量的方法 | |
RU2014121884A (ru) | Хроматография перегрузки и элюирования | |
JP7361754B2 (ja) | クロマトグラフィーにおけるバイオバーデンを低減するための組成物および方法 | |
RU2019109975A (ru) | Способы очистки антител | |
JP2018510867A5 (hr) | ||
RU2016112549A (ru) | Способ для повторного использования хроматографии | |
JP2017521389A5 (hr) | ||
RU2014121886A (ru) | Устройство для обработки курительного изделия и картридж для него | |
JP2016506952A (ja) | タンパク質調製物の凝集体含有量を低減する方法 | |
KR20150023297A (ko) | 고상 우레이드에 대한 생물학적 표적의 선택적 결합 | |
JP2014507368A5 (hr) | ||
JP2016514101A (ja) | タンパク質製剤からエンドトキシンを除去するための物質および方法 | |
CN103275217A (zh) | 磁珠法快速纯化抗体 | |
CN104560895A (zh) | 猪圆环病毒疫苗的纯化方法 | |
CN106279412A (zh) | 一种抗vegf类单克隆抗体的纯化方法 | |
CN108101982A (zh) | 一种单克隆抗体的纯化方法 |